

PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

3-5-02

Date

Cynthia Hagen

Cynthia Hagen

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Adler et al.  
Serial No. : Unknown (Parent: 09/636,399)  
Filed : Herewith (Parent: August 10, 2000)  
For : NOVEL BETA-DEFENSINS  
Examiner : Unknown  
Art Unit : Unknown  
Docket No. : 97-44D1  
Date : March 5, 2002

Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Sir:

Prior to taking up the above-identified application for examination, please amend the application as follows:

**In the Specification**

Please replace the paragraph beginning at page 1, line 8, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate changes made.

The present application is a divisional application of U.S. Patent Application Serial No. 09/636,399, filed August 10, 2000, which is a continuation-in-part of U.S. Patent Application No. 09/344,097, filed on June 25, 1999, which is a continuation-in-part of U.S. Patent Application No. 09/150,786, filed on September 10, 1998, which is related to

Applicants: Adler et al.

Serial No.: Unknown (Parent: 09/636,399)

Docket No.: 97-44D1

For: NOVEL BETA-DEFENSINS

---

Provisional Applications 60/058,335, filed on September 10, 1997 and 60/064,294, filed on November 5, 1997, all of which are herein incorporated by reference. Under 35 U.S.C. §119(e)(1), this application claims benefit of said Provisional Applications.

Please replace the paragraph beginning at page 3, line 36, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate changes made.

Within one aspect the invention provides an isolated protein comprising a polypeptide that is at least 80% identical to a polypeptide selected from the group consisting of: a) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 65 of SEQ ID NO:2; b) a polypeptide having the sequence of amino acid residue 19 to amino acid residue 65 of SEQ ID NO:2; c) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 65 of SEQ ID NO:2; d) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10; e) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10; and f) a polypeptide having the sequence of amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10; wherein the polypeptide has cysteine residues corresponding to amino acid residues 33, 40, 45, 55, 62 and 63 of SEQ ID NOs:2 or 10. Within one embodiment the protein comprises a polypeptide having the sequence selected from the group consisting of: a) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10; b) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10; and c) a polypeptide having the sequence of amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10.

Please replace the paragraph beginning at page 5, line 14, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate changes made.

Within another aspect is provided an isolated polynucleotide molecule encoding a protein, the polynucleotide molecule consisting of a coding strand and a

Applicants: Adler et al.

Serial No.: Unknown (Parent: 09/636,399)

Docket No.: 97-44D1

For: NOVEL BETA-DEFENSINS

---

complementary non-coding strand, wherein the polynucleotide molecule encodes a polypeptide that is at least 80% identical to the amino acid sequence to a polypeptide selected from the group consisting of: a) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 65 of SEQ ID NO:2; b) a polypeptide having the sequence of amino acid residue 19 to amino acid residue 65 of SEQ ID NO:2; c) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 65 of SEQ ID NO:2; d) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10; e) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10; and f) a polypeptide having the sequence of amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10; wherein the polypeptide has cysteine residues corresponding to amino acid residues 33, 40, 45, 55, 62 and 63 of SEQ ID NOs:2 or 10.

Please replace the paragraph beginning at page 74, line 28, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate changes made.

A 45 amino acid residue zamp1 peptide (residues 23 to 67 of SEQ ID NO:10) was synthesized by solid phase peptide synthesis using a model 431A Peptide Synthesizer (Applied Biosystems/Perkin Elmer, Foster City, CA). Fmoc-Lysine(Boc) resin (0.52 mmol/g; Anaspec Inc., San Jose, CA) was used as the initial support resin. 1 mmol Amino acid cartridges (Anaspec Inc., San Jose, CA and Applied Biosystems/Perkin Elmer, Foster City, CA) were used for synthesis. 2-(1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (HBTU), 1-Hydroxy-benzotriazole (HOBr), 2 M N,N-Diisopropylethylamine, N-Methylpyrrolidone, Dichloromethane (all from Applied Biosystems/Perkin Elmer, Foster City, CA), along with piperidine (Aldrich Chemical Co., St. Louis, MO) and 0.5 M acetic anhydride capping solution (Advanced ChemTech, Louisville, KY), were used as synthesis reagents.

Applicants: Adler et al.

Serial No.: Unknown (Parent: 09/636,399)

Docket No.: 97-44D1

For: NOVEL BETA-DEFENSINS

---

REMARKS

The Examiner is respectfully requested to consider and to enter the above amendments. The specification has been amended to correct a typographical error.

Summary

It is respectfully submitted that claims 1-7 and 21-43 are in condition for allowance, and notification to that effect is earnestly solicited. The Examiner is invited to contact Applicants' Representative at (206) 402-6540, if it is believed that prosecution of this application may be assisted thereby.

Respectfully Submitted,



Brian J. Walsh  
Registration No. 45,543

Enclosures:

Express Mail Certificate

Filing Under 37 C.F.R. §1.53(b) (in duplicate)

Patent Application (87 pages)

Figures (2 sheets of drawings)

Unexecuted Combined Declaration and Power of Attorney

Sequence Listing (33 pages)

Sequence Listing Diskette

Preliminary Amendment and accompanying Appendix A

Postcard

**APPENDIX A – SPECIFICATION AMENDMENTS WITH NOTATIONS TO  
INDICATE CHANGES MADE**  
**Applicant(s): Adler et al.**  
**File No. 97-44D1**  
**For: NOVEL BETA-DEFENSINS**

---

Amendments to the following are indicated by underlining what has been added and bracketing what has been deleted. Additionally, all amendments have been shaded.

**In the Specification**

The paragraph beginning at page 1, line 8, under the heading “REFERENCE TO RELATED APPLICATIONS” has been amended as follows:

[This] The present application is a divisional application of U.S. Patent Application Serial No. 09/616,399, filed August 10, 2000, which is a continuation-in-part of U.S. Patent Application No. 09/344,097, filed on June 25, 1999, which is a continuation-in-part of U.S. Patent Application No. 09/150,786, filed on September 10, 1998, which is related to Provisional Applications 60/058,335, filed on September 10, 1997 and 60/064,294, filed on November 5, 1997, all of which are herein incorporated by reference. Under 35 U.S.C. §119(e)(1), this application claims benefit of said Provisional Applications.

The paragraph beginning at page 3, line 36, has been amended as follows:

Within one aspect the invention provides an isolated protein comprising a polypeptide that is at least 80% identical to a polypeptide selected from the group consisting of: a) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 65 of SEQ ID NO:2; b) a polypeptide having the sequence of amino acid residue 19 to amino acid residue 65 of SEQ ID NO:2; c) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 65 of SEQ ID NO:2; d) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10; e) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10; and f) a polypeptide having the sequence of amino acid residue 23 to amino acid residue 67 of SEQ ID NO:[2]10; wherein the polypeptide has cysteine residues corresponding to amino acid residues

Applicants: Adler et al.

Serial No.: Unknown (Parent: 09/636,399)

Filed: Herewith (Parent: August 10, 2000)

Docket No.: 97-44D1

For: NOVEL BETA-DEFENSINS

---

33, 40, 45, 55, 62 and 63 of SEQ ID NOs:2 or 10. Within one embodiment the protein comprises a polypeptide having the sequence selected from the group consisting of: a) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10; b) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10; and c) a polypeptide having the sequence of amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10.

The paragraph beginning at page 5, line 14, has been amended as follows:

Within another aspect is provided an isolated polynucleotide molecule encoding a protein, the polynucleotide molecule consisting of a coding strand and a complementary non-coding strand, wherein the polynucleotide molecule encodes a polypeptide that is at least 80% identical to the amino acid sequence to a polypeptide selected from the group consisting of: a) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 65 of SEQ ID NO:2; b) a polypeptide having the sequence of amino acid residue 19 to amino acid residue 65 of SEQ ID NO:2; c) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 65 of SEQ ID NO:2; d) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10; e) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10; and f) a polypeptide having the sequence of amino acid residue 23 to amino acid residue 67 of SEQ ID NO:[2]10; wherein the polypeptide has cysteine residues corresponding to amino acid residues 33, 40, 45, 55, 62 and 63 of SEQ ID NOs:2 or 10.

The paragraph beginning at page 74, line 28, has been amended as follows:

A 45 amino acid residue zamp1 peptide (residues 23 to 67 of SEQ ID NO:[2]10) was synthesized by solid phase peptide synthesis using a model 431A Peptide Synthesizer (Applied Biosystems/Perkin Elmer, Foster City, CA). Fmoc-Lysine(Boc) resin (0.52 mmol/g; Anaspec Inc., San Jose, CA) was used as the initial

Applicants: Adler et al.  
Serial No.: Unknown (Parent: 09/636,399)  
Filed: Herewith (Parent: August 10, 2000)  
Docket No.: 97-44D1  
For: NOVEL BETA-DEFENSINS

---

support resin. 1 mmol Amino acid cartridges (Anaspec Inc., San Jose, CA and Applied Biosystems/Perkin Elmer, Foster City, CA) were used for synthesis. 2-(1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyuroniumhexafluorophosphate (HBTU), 1-Hydroxy-benzotriazole (HOBr), 2 M N,N-Diisopropylethylamine, N-Methylpyrrolidone, Dichloromethane (all from Applied Biosystems/Perkin Elmer, Foster City, CA), along with piperidine (Aldrich Chemical Co., St. Louis, MO) and 0.5 M acetic anhydride capping solution (Advanced ChemTech, Louisville, KY), were used as synthesis reagents.